Kraaij, Tineke https://orcid.org/0000-0002-0874-3365
Nilsson, Sara C.
van Kooten, Cees
Okrój, Marcin
Blom, Anna M
Teng, YK Onno
Clinical trials referenced in this document:
Documents that mention this clinical trial
OP0302 Significant reductions of pathogenic autoantibodies by synergetic rituximab and belimumab treatment effectively inhibits neutrophil extracellular traps in severe, refractory sle - the synbiose study
https://doi.org/10.1136/annrheumdis-2017-eular.5706
Measuring plasma C4D to monitor immune complexes in lupus nephritis
https://doi.org/10.1136/lupus-2019-000326
From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?
https://doi.org/10.1136/annrheumdis-2021-221270
OP0042 LONG-TERM EFFECTS OF SYNERGETIC B CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS
https://doi.org/10.1136/annrheumdis-2019-eular.5664
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
https://doi.org/10.2215/cjn.01070118
SAT0258 Synergetic b-cell immunomodulation with rituximab and belimumab is clinically effective in severe and refractory systemic lupus erythematosus – the synbiose proof-of-concept study
https://doi.org/10.1136/annrheumdis-2017-eular.2364
Funding for this research was provided by:
Nierstichting (KJPB12.028 & 17OKG04)
Swedish Rheumatism Association
National Science Centre Poland (2014/14/E/NZ6/00182)
King Gustav V´s 80th Anniversary Foundation
Swedish Research Council (2016-01142)
Netherlands Organization for Scientific Research (90713460)